November 13, 2014, DAVIS, CA — Marrone Bio Innovations, Inc. (MBI), (NASDAQ: MBII), a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets, is pleased to announce that its Marrone Michigan Manufacturing (M3) facility in Bangor, Michigan has received a 2014 “Green Agribusiness Award” from the Michigan Agri-Business Association (MABA).
The awards recognize companies for pursuing sustainability requirements across the scope of agricultural production that help agriculture further protect water quality and the Great Lakes, and achieve the greatest possible yields while protecting the environment.
“Every day, consumers are more connected to our food system and they want to know that Michigan agriculture is producing food in a sustainable way,” said Jim Byrum, President of MABA. “In addition, our industry knows the value of protecting our air, water and Great Lakes for coming generations. By pursuing a wide range of sustainability criteria under the Green Agribusiness Designation Program, companies across the state, such as Marrone Bio Innovations, are leading the way on this important issue.”
The M3 facility, which held its Grand Opening on July 1, 2014, is a wholly-owned subsidiary of MBI. Currently three MBI product lines are being produced at the M3 facility: REGALIA® and REGALIA Rx®, which are biofungicides, GRANDEVO®, which is a bioinsecticide and ZEQUANOX®, which is a biomolluscicide to control invasive zebra and quagga mussels.
“On behalf of the entire MBI team, I would like to thank the Michigan Agri-Business Association for recognizing our contributions to sustainable agriculture,” said Gordon Grove, MBI’s M3 Plant Manager. “Southwest Michigan is positioned at the forefront of a growing global movement to firmly establish biologically based technologies as the foundation in agriculture, turf, ornamental and water treatment markets. As the world looks for answers to sustainably feed 9 billion people, M3 and Southwest Michigan will be providing safe, smart and effective solutions to big challenges confronting humanity and the environment.”
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. (NASDAQ: MBII) is a leading provider of bio-based pest management and plant health products for the agriculture, turf and ornamental and water treatment markets. Our effective and environmentally responsible solutions help customers operate more sustainably while controlling pests, improving plant health, and increasing crop yields. We have a proprietary discovery process, a rapid development platform, and a robust pipeline of pest management and plant health product candidates. At Marrone Bio Innovations we are dedicated to pioneering better biopesticides that support a better tomorrow for users around the globe. For more information, please visit www.marronebio.com.
As previously disclosed in the Company’s Form 8-K dated September 3, 2014, the Company’s Audit Committee has commenced an internal investigation. The Audit Committee has not yet concluded its investigation and the Company does not expect it will be in a position to discuss financial results until after the investigation is completed.
The uncertainty surrounding the timing and results of the Audit Committee investigation could impact the timing of Company’s discussion of its financial results. Additional relevant information concerning developments in the Audit Committee investigation may be found in the Company’s filings with the Securities and Exchange Commission from time to time.
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements relating to market size and the results from the field trials. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements, including the difficulty in predicting the outcome of product research and development efforts and regulatory approvals. Additional relevant information concerning risks can be found in the in the Form 10-K that the Company filed with the Securities and Exchange Commission on March 25, 2014.